{
    "clinical_study": {
        "@rank": "21785", 
        "acronym": "TAME-AL", 
        "arm_group": [
            {
                "arm_group_label": "Epigallocatechin-3-gallate (EGCG)", 
                "arm_group_type": "Experimental", 
                "description": "EGCG 400 mg/d p.o. for 3 months; 800 mg/d p.o. for 3 months, 1200 mg/d p.o. for 6 months"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "capsules\nDose:\n400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
            }
        ], 
        "brief_summary": {
            "textblock": "Efficacy and safety of epigallocatechin-3-gallate (EGCG) in patients with cardiac amyloid\n      light-chain (AL) amyloidosis. Evaluation of clinical efficacy of EGCG intake using a pretest\n      posttest comparison of left ventricular amyloid mass (g/m2) measured by cardiac MRI."
        }, 
        "brief_title": "A Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)", 
        "condition": [
            "Light Chain (AL) Amyloidosis", 
            "Cardiac Involvement"
        ], 
        "condition_browse": {
            "mesh_term": "Amyloidosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Biopsy proven systemic AL amyloidosis.\n\n          -  Cardiac involvement with septum thickness more than 12 mm (without other causes as\n             published by Gertz et al., hypertension or other potential causes of left ventricular\n             hypertrophy)\n\n          -  Previously treated with chemotherapy, induced at least a very good partial remission\n             of the underlying monoclonal plasma cell or B cell disorder.\n\n          -  GPT and GOT less than 3-times ULN.\n\n          -  Life expectancy more than 12 month.\n\n          -  Ability of subject to understand character and individual consequences of the\n             clinical trail.\n\n          -  Written informed consent.\n\n          -  For women with childbearing potential and men, adequate contraception.\n\n        Exclusion Criteria:\n\n          -  Age less than 18 years.\n\n          -  Concomitant multiple myeloma stage 2 and 3 (Salmon and Durie)\n\n          -  Concurrent chemotherapy necessary\n\n          -  Time to last chemotherapy more than 6 months.\n\n          -  Chronic liver disease, Bilirubin over 1,5 mg/dl\n\n          -  Not able to visit Amyloidosis Clinic in Heidelberg every 3 months.\n\n          -  History of hypersensitivity to the investigational product or to any substance with\n             similar chemical structure or to any excipient present in the pharmaceutical form of\n             the investigational medicinal product.\n\n          -  Participation in other clinical trials or observation period of competing trials,\n             respectively.\n\n          -  Pregnant or nursing women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015312", 
            "org_study_id": "TAME-AL", 
            "secondary_id": "2012-004520-38"
        }, 
        "intervention": {
            "arm_group_label": "Epigallocatechin-3-gallate (EGCG)", 
            "description": "Pharmaceutical formulation: capsules\nDose:\n400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months", 
            "intervention_name": "Epigallocatechin-3-gallate (EGCG)", 
            "intervention_type": "Drug", 
            "other_name": [
                "Epigallocatechin gallate", 
                "EGCG", 
                "Epigallocatechin 3-gallate", 
                "Tea catechin", 
                "Epigallocatechin-3-gallate"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Epigallocatechin gallate"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Amyloidosis", 
        "lastchanged_date": "December 12, 2013", 
        "location": {
            "contact": {
                "email": "stefan.schoenland@med.uni-heidelberg.de", 
                "last_name": "Stefan Sch\u00f6nland, MD", 
                "phone": "+49 6221 56 8009"
            }, 
            "contact_backup": {
                "email": "ute.hegenbart@med.uni-heidelberg.de", 
                "last_name": "Ute Hegenbart, MD", 
                "phone": "+49 6221 56 8009"
            }, 
            "facility": {
                "address": {
                    "city": "Heidelberg", 
                    "country": "Germany", 
                    "state": "Baden-W\u00fcrttemberg", 
                    "zip": "69120"
                }, 
                "name": "University Hospital of Heidelberg; Medical Department V"
            }, 
            "investigator": [
                {
                    "last_name": "Stefan Sch\u00f6nland, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Ute Hegenbart, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)", 
        "overall_contact": {
            "email": "stefan.schoenland@med.uni-heidelberg.de", 
            "last_name": "Stefan Sch\u00f6nland, MD", 
            "phone": "0049 6221 56 8009"
        }, 
        "overall_contact_backup": {
            "email": "ute.hegenbart@med.uni-heidelberg.de", 
            "last_name": "Ute Hegenbart, MD", 
            "phone": "0049 6221 56 8009"
        }, 
        "overall_official": {
            "affiliation": "University Hospital of Heidelberg", 
            "last_name": "Stefan Sch\u00f6nland, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary analysis to compare the 12 month change in left ventricular mass between the two treatment arms will be performed by a one-sided two-sample t test at a significance level of 0.025.", 
            "measure": "compare the 12 month change in left ventricular mass", 
            "safety_issue": "No", 
            "time_frame": "12 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015312"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital Heidelberg", 
            "investigator_full_name": "Florian Michel", 
            "investigator_title": "Study Coordinator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Quality of Life, evaluated with EORTC-QLQ-C30", 
                "measure": "Change in Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 month"
            }, 
            {
                "description": "Number of adverse events according to CTC criteria (Version 4.0)", 
                "measure": "safety of EGCG", 
                "safety_issue": "Yes", 
                "time_frame": "12 month"
            }, 
            {
                "description": "cardiac troponin T (hsTNT), NTproBNP", 
                "measure": "change in cardiac biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Month"
            }, 
            {
                "description": "Hematological Response according to Palladini et al 2012", 
                "measure": "improvement of hematological remission", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Month"
            }, 
            {
                "description": "Organ response according to Gertz et al 2005", 
                "measure": "Organ response in affected organs other than heart", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Month"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "12 Month"
            }
        ], 
        "source": "University Hospital Heidelberg", 
        "sponsors": {
            "collaborator": {
                "agency": "German Federal Ministry of Education and Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Florian Michel", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}